Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study

Abstract

AbstractIntroductionProstate cancer is the most common cancer in men. Thirty to forty‐seven percent of patients treated with exclusive radiotherapy for prostate cancer will experience intraprostate recurrence. The use of radiotherapy in stereotactic conditions allows millimetric accuracy in irradiation to the target zone that minimizes the dose to organs at risk. In this study, we evaluated the clinical outcome of prostatic reirradiation with stereotactic body radiation therapy (SBRT) in patients with intraprostatic recurrence initially treated by radiotherapy.MethodThis single‐center retrospective study included 41 patients diagnosed with exclusive local recurrence of prostate cancer after radiotherapy and treatedby stereotactic Cyberknife irradiation. The objective of this study was to assess the efficacy and the safety of stereotactic reirradiation for patients with intraprostatic recurrence initially treated with radiotherapy.ResultsMedian follow‐up was 35 months. The 2‐year biochemical relapse‐free survival was 72.89%, the 2‐year local recurrence free survival was 93.59%, the 2‐year local regional recurrence‐free survival was 85.24%, and the 2‐year metastasis‐free survival was to 91.49%. The analysis of toxicities showed a good tolerance of stereotactic irradiation. Urinary and gastro‐intestinal adverse events was mostly of grades 1–2 (CTCAEv4). Grade 3 toxicity occurred in one to two patients.ConclusionStereotactic reirradiation appears effective and well‐tolerated for local recurrence of prostate cancer and might allow to delay the introduction of hormonal therapy and its side effects.